Reliability and Clinical Impact of the Normalization of the Prothrombin Times in Oral Anticoagulant Control

Summary

In 1983, the World Health Organization (WHO) published recommendations for normalization, in oral anticoagulant control, of the prothrombin time (PT). The common denominator is the International Sensitivity Index (ISI) of a thromboplastin, obtained by means of thromboplastin calibration. The common scale is that of the International Normalized Ratio (INR). The INR is the PT ratio Patient PT/normal PT which would have been found normal PT with the WHO primary international reference preparation (IRP) 67/40. The reliability of the INR depends on the extent of calibration precision, patient-specific influences, as well as interlaboratory variation in the PT determination. Under well-controlled conditions the overall coefficient of variation (CV) of the INR is 11-13.5%, if thromboplastins of ISI ≃ 1 are used. For so-called low-sensitivity thromboplastins (ISI ≃ 2-2.5), the overall variation is larger due to a large between-laboratory variation of the measured PT-ratios

The user of thromboplastin will be provided with a chart or graph enabling him to convert the conventional terms used for expressing PTs into INRs. For quality assurance, and to prepare his own calibration chart if necessary, he should check normalization by means of control plasmas to which INRs have been assigned.

There is sufficient clinical evidence to express optimal therapeutic ranges in terms of INR. Manufacturers should revise and adapt their inserts where necessary in order to conform to these requirements.

Key words

Oral anticoagulant control - Prothrombin time normalization - Thromboplastin calibration - Therapeutic range

• References

• 1 Loeliger EA, Lewis SM. Progress in laboratory control of oral anticoagulants. Lancet 1982; 2: 318-320
• 2 Kirkwood TB L. Calibration of reference thromboplastins and standardisation of the prothrombin time ratio. Thromb Haemostas 1983; 49: 238-244
• 3 WHO Expert Committee on Biological Standardization. Thirty-third Report. Technical Report Series 687. WHO; Geneva; 1983
• 4 WHO Expert Committee on Biological Standardization. Twenty-eight Report. Technical Report Series 610. WHO; Geneva: 1983
• 5 WHO Expert Committee on Biological Standardization. Thirtieth Report. Technical Report Series 638. WHO; Geneva: 1983
• 6 Loeliger EA, Van den Besselaar AM H P, Hermans J, Van der Velde EA. Certification of three reference materials for thromboplastins. BCR information. Commission of the European Communities; Brussels: 1983
• 7 Thomson JM, Stevenson KJ, Tomenson JA. Report on proposed second WHO international reference thromboplastin, human, plain, to replace the WHO international reference preparation, human, combined. WHO; Geneva: 1983
• 8 WHO Expert Committee on Biological Standardization. Thirty-fourth Report. Technical Report Series 700. WHO; Geneva: 1983
• 9 Hermans J, Van den Besselaar AM H P, Loeliger EA, Van der Velde EA. A collaborative calibration study of reference materials for thromboplastins. Thromb Haemostas 1983; 50: 712-717
• 10 Van den Besselaar AM H P, Van der Velde EA. The manufacturer’s calibration study. In: Thromboplastin Calibration and Oral Anticoagulant Control. Van den Besselaar AM H P, Gralnick HR, Lewis SM. (Eds) Martinus Nijhoff; The Hague: 1984. pp 127-149
• 11 Poller L. The British system for anticoagulant control. Thrombos Diathes Haemorrh 1975; 33: 157-162
• 12 Van Dijk-Wierda CA, Loeliger EA, Meilof J, Roos J. Anticoagulant control in The Netherlands. Lancet 1981; 1: 1321-1322
• 13 Loeliger EA, Van der Hoeff-van Halem R, Van Halem-Visser LP. Thromboplastin calibration. Experience of the Dutch Reference Laboratory for Anticoagulant Control Thromb Haemostas 1978; 40: 272-287
• 14 Van den Besselaar AM H P, Van Halem-Visser LP, Hoekstra-Schuman M, Van der Marel-van Nieuwkoop W, Loeliger EA. Simplified thromboplastin calibration. Further experience of the Dutch Reference Laboratory for Anticoagulant Control Thromb Haemostas 1980; 43: 53-57
• 15 Van den Besselaar AM H P, Loeliger EA, Poller L, Thomson JM, Tomenson JA. Standardisation of oral anticoagulant treatment. Br Med J 1984; 288: 486-487
• 16 Tomenson JA, Thomson JM, Poller L. The British system of oral anticoagulant control and its relation with the WHO system: calibration of the proposed second WHO International Reference Thromboplastin (BCT/253). In: Thromboplastin Calibration and Oral Anticoagulant Control. Van den Besselaar AM H P, Gralnick HR, Lewis SM. (Eds) Martinus Nijhoff; The Hague: 1984. pp 165-194
• 17 Boekhout-Mussert MJ, Van der Kolk-Schaap PJ, Hermans J, Loeliger EA. Prospective double-blind clinical trial of bovine, human, and rabbit thromboplastins in monitoring long-term oral anticoagulation. Am J Clin Pathol 1981; 75: 297-303
• 18 Zucker S, Brosious E, Cooper GR. One-stage prothrombin time survey. Am J Clin Pathol 1970; 53: 340-347
• 19 Beeser H, Merten R, Drescher H, Fischer J. A German prothrombin time proficiency program. Thrombos Diathes Haemorrh 1975; 33: 152-156
• 20 Van Dijk-Wierda CA, Hermans J, Loeliger EA, Roos J. Interlaboratory oral anticoagulant quality assessment by the Netherlands Foundation of Thrombosis Services. Thromb Haemostas 1977; 37: 509-522
• 21 Tomenson JA. A statistician’s independent evaluation. In: Thromboplastin Calibration and Oral Anticoagulant Control. Van denBesselaar AM H P, Gralnick HR, Lewis SM. (Eds) Martinus Nijhoff; The Hague: 1984. pp 87-108
• 22 Goguel A. Contrôle de qualité du temps de Quick. Renseignements fournis par les confrontations interlaboratoires “Etalonorme” 1973 à 1975 Feuillets de Biologie 1976; 17: 31-43
• 23 Goguel A. In: Triplett DA. (ed) Standardization of Coagulation Assays: An Overview. College of American Pathologists; Skokie, Illinois: 1982. pp 120-124
• 24 The International Committee on Thrombosis and HaemostasisThe International Committee for Standardization in Hematology. Prothrombin time standardization: Report of the Expert Panel on Oral Anticoagulant Control. Thromb Haemostas 1979; 42: 1073-1114
• 25 Duckert F, Marbet GA. Le contrôle du traitement aux anticoagulants oraux. La zone thérapeutique Méd et Hyg 1977; 35: 911
• 26 Duckert F, Marbet GA. Die Kontrolle der oralen Antikoagulantien. Der therapeutische Bereich. Schweiz: Rundschau Med (Praxis); 1977. 10 293-294
• 27 Loeliger EA. The optimal therapeutic range in oral anticoagulation. History and proposal Thromb Haemostas 1979; 42: 1141-1152
• 28 Sixty Plus Reinfarction Study Research Group. A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet 1980; 2: 989-994
• 29 Poller L. Oral anticoagulant therapy. In: Haemostasis and Thrombosis. Bloom AL, Thomas DP. (Eds) Churchill Livingstone; Edinburgh: 1981. pp 725-736
• 30 Blackburn EK. Long-term anticoagulant therapy. Prescr J 1977; 17: 73-74
• 31 Marti P, Beck EA. Standardisierungsprobleme bei der Überwachung der oralen Antikoagulation durch die Thromboplastinzeit nach Quick: Versuch einer Standortbestimmung für die Schweiz. Schweiz Med Wschr 1983; 113: 1593-1597
• 32 Van den Besselaar AM H P, Loeliger EA. Standardisierungsprobleme bei der Überwachung der oralen Antikoagulation durch die Thromboplastinzeit nach Quick: Versuch einer Standortbestimmung für die Schweiz. Schweiz Med Wschr 1984; 114: 454
• 33 Tabemer DA, Poller L, Burslem RW, Jones JB. Oral anticoagulants controlled by the British comparative thromboplastin versus low-dose heparin in prophylaxis of deep vein thrombosis. Br Med J 1978; 1: 272-274
• 34 Francis CW, Marder JD, Evarts McC, Yaukoolbodi S. Two-step warfarin therapy. Prevention of postoperative venous thrombosis without excessive bleeding JAMA 1983; 249: 374-378
• 35 Hull R, Hirsh J, Jay R. et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982; 307: 1676-1681
• 36 Sixty Plus Reinfarction Study Research Group. Risks of long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet 1982; 1: 64-68
• 37 Forfar JC. A 7-year analysis of haemorrhage in patients on long-term anticoagulant treatment. Br Heart J 1979; 42: 128-132
• 38 Wintzen AR, Tijssen JG P. Subdural haematoma and oral anticoagulant therapy. Arch Neurol 1982; 39: 69-72
• 39 Wintzen AR, De Jonge H, Loeliger EA, Bots GT A M. The risk of intracerebral haemorrhage during oral anticoagulant treatment; a population study. Ann Neurol 1984; 16: 553-558